Dashboard
Manage Tickers

COGT Cogent Biosciences, Inc.

Nasdaq cogentbio.com


$ 33.95 $ -0.29 (-0.86 %)    

Friday, 14-Nov-2025 15:54:52 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 608.45 $ 0.46 (0.08 %)
DIA $ 471.65 $ -2.94 (-0.62 %)
SPY $ 671.62 $ -0.11 (-0.02 %)
TLT $ 88.93 $ -0.51 (-0.57 %)
GLD $ 375.82 $ -6.91 (-1.8 %)
$ 33.54
$ 32.06
$ 34.02 x 1,003
$ 34.00 x 61
$ 32.70 - $ 36.02
$ 3.72 - $ 36.29
5,451,474
na
4.78B
$ 0.81
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-07-2025 09-30-2025 10-Q
2 08-05-2025 06-30-2025 10-Q
3 05-06-2025 03-31-2025 10-Q
4 02-25-2025 12-31-2024 10-K
5 11-12-2024 09-30-2024 10-Q
6 08-06-2024 06-30-2024 10-Q
7 05-07-2024 03-31-2024 10-Q
8 02-26-2024 12-31-2023 10-K
9 11-07-2023 09-30-2023 10-Q
10 08-08-2023 06-30-2023 10-Q
11 05-09-2023 03-31-2023 10-Q
12 03-14-2023 12-31-2022 10-K
13 11-14-2022 09-30-2022 10-Q
14 08-09-2022 06-30-2022 10-Q
15 05-10-2022 03-31-2022 10-Q
16 03-15-2022 12-31-2021 10-K
17 11-10-2021 09-30-2021 10-Q
18 08-16-2021 06-30-2021 10-Q
19 05-12-2021 03-31-2021 10-Q
20 03-16-2021 12-31-2020 10-K
21 11-09-2020 09-30-2020 10-Q
22 08-11-2020 06-30-2020 10-Q
23 05-11-2020 03-31-2020 10-Q
24 03-26-2020 12-31-2019 10-K
25 11-12-2019 09-30-2019 10-Q
26 08-12-2019 06-30-2019 10-Q
27 05-13-2019 03-31-2019 10-Q
28 03-28-2019 12-31-2018 10-K
29 11-13-2018 09-30-2018 10-Q
30 08-13-2018 06-30-2018 10-Q
31 05-14-2018 03-31-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-maintains-buy-on-cogent-biosciences-raises-price-target-to-50
HC Wainwright & Co. Maintains Buy on Cogen...
11/13/2025 12:57:57

HC Wainwright & Co. analyst Robert Burns maintains Cogent Biosciences (NASDAQ:COGT) with a Buy and raises the price targ...

reported-earlier-cogent-biosciences-announces-pricing-of-public-offerings-of-968m-shares-at-31-each-and-200m-1625-convertible-senior-notes-due-2031-raising-4753m
Reported Earlier, Cogent Biosciences Annou...
11/12/2025 07:04:24

baird-maintains-neutral-on-cogent-biosciences-raises-price-target-to-34
Baird Maintains Neutral on Cogent Bioscien...
11/11/2025 13:12:48

Baird analyst Colleen Kusy maintains Cogent Biosciences (NASDAQ:COGT) with a Neutral and raises the price target from $14 to...

leerink-partners-maintains-outperform-on-cogent-biosciences-raises-price-target-to-50
Leerink Partners Maintains Outperform on C...
11/10/2025 21:21:41

Leerink Partners analyst Andrew Berens maintains Cogent Biosciences (NASDAQ:COGT) with a Outperform and raises the price tar...

cogent-biosciences-announces-200m-senior-notes-offering-200m-common-stock-offering
Cogent Biosciences Announces $200M Senior ...
11/10/2025 21:15:08

Cogent Biosciences, Inc. ("Cogent") (Nasdaq: COGT), a biotechnology company focused on developing precision therapies f...

Core News & Articles
12 Health Care Stocks Moving In Monday's I...
11/10/2025 17:07:01

gold-jumps-over-2-dole-shares-gain-after-q3-results
Gold Jumps Over 2%; Dole Shares Gain After...
11/10/2025 17:01:53

cogent-biosciences-lead-cancer-drug-cuts-disease-progression-or-death-risk-by-50-in-stomach-cancer-trial
Cogent Biosciences' Lead Cancer Drug Cuts ...
11/10/2025 15:28:05

Cogent Biosciences stock rises as bezuclastinib plus Sutent shows 50% lower progression risk and strong efficacy in Phase 3 GIS...

pagaya-technologies-posts-upbeat-q3-results-joins-ironwood-pharmaceuticals-treehouse-foods-and-other-big-stocks-moving-higher-on-monday
Pagaya Technologies Posts Upbeat Q3 Result...
11/10/2025 15:01:52

sp-500-surges-1-tyson-foods-posts-upbeat-earnings
S&P 500 Surges 1%; Tyson Foods Posts Upbea...
11/10/2025 14:43:46

trading-halt-halt-status-updated-at-71500-am-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 7:15:...
11/10/2025 12:15:04

cogent-biosciences-combination-of-bezuclastinib-plus-sunitinib-in-phase-3-peak-study-reaches-median-progression-free-survival-of-165-months-company-on-track-to-submit-new-drug-application-to-us-fda-for-bezuclastinib-in-intolerant-gastrointestinal-stromal-tumors
Cogent Biosciences Combination Of Bezuclas...
11/10/2025 12:11:49

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defi...

trading-halt-halted-at-65500-am-et---trading-halt-halt-news-pending
Trading Halt: Halted at 6:55:00 a.m. ET - ...
11/10/2025 11:55:04

cogent-biosciences-files-for-mixed-shelf-offering-size-not-disclosed
Cogent Biosciences Files For Mixed Shelf O...
11/07/2025 21:54:17

-SEC Filing

hc-wainwright--co-reiterates-buy-on-cogent-biosciences-maintains-21-price-target
HC Wainwright & Co. Reiterates Buy on Coge...
11/04/2025 13:09:50

HC Wainwright & Co. analyst Robert Burns reiterates Cogent Biosciences (NASDAQ:COGT) with a Buy and maintains $21 price ...

cogent-biosciences-announces-updated-preclinical-data-from-the-cos-potent-and-selective-pan-krason-inhibitor-in-a-poster-presentation-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-says-poster-highlights-that-cgt1815-demonstrates-superior-efficacy-in-krasg12d-and-krasg12v-tumor-growth-inhibition-studies-when-compared-to-rmc-6236
Cogent Biosciences Announces Updated Precl...
10/24/2025 16:33:21

Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defin...

jp-morgan-maintains-overweight-on-cogent-biosciences-raises-price-target-to-44
JP Morgan Maintains Overweight on Cogent B...
10/21/2025 11:33:04

JP Morgan analyst Anupam Rama maintains Cogent Biosciences (NASDAQ:COGT) with a Overweight and raises the price target from ...

cogent-biosciences-receives-fda-breakthrough-therapy-designation-for-bezuclastinib-in-nonadvanced-systemic-mastocytosis
Cogent Biosciences Receives FDA Breakthrou...
10/20/2025 12:33:39

stifel-initiates-coverage-on-cogent-biosciences-with-hold-rating-announces-price-target-of-16
Stifel Initiates Coverage On Cogent Biosci...
10/16/2025 13:41:14

Stifel analyst Laura Prendergast initiates coverage on Cogent Biosciences (NASDAQ:COGT) with a Hold rating and announces Pri...

raymond-james-initiates-coverage-on-cogent-biosciences-with-strong-buy-rating-announces-price-target-of-30
Raymond James Initiates Coverage On Cogent...
09/03/2025 16:46:55

Raymond James analyst Chris Raymond initiates coverage on Cogent Biosciences (NASDAQ:COGT) with a Strong Buy rating and anno...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION